164 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
and intentions regarding, among other things, the potential benefits of APHEXDA®, the ongoing commercialization of APHEXDA and the plans and objectives
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
, the potential benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives of management for future operations and expectations
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
other things, the potential benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives of management for future
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential benefits of APHEXDA
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
benefits of APHEXDA, the execution of the launch of APHEXDA and the plans and objectives of management for future operations and expectations
6-K
EX-10.1
qjzgdutjm85z12yui3or
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-10.2
17rr8any2iqjbraf
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
qd9h 42z95mwm
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
4ar67j1 sfryn2eegf
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
qs3qeyxko30yxewl
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
tcmswnxwp yev
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
g0pm9aqif 61p0w7
16 Feb 24
Current report (foreign)
7:07am
F-3
3jm6e0n7zk
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
tllfcmf
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
yfk kl0aia
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
4mhk0 rtyp5fzfly
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
a25tjlav7ap
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
642w5mzi
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am